FDA approves new pancreatic cancer drug that could extend patients' lives
Summary
The U.S. Food and Drug Administration (FDA) has approved a new pill called daraxonrasib (brand name Rasonque) to treat advanced pancreatic cancer. This drug blocks a mutated protein causing tumor growth and has nearly doubled survival time for patients compared to chemotherapy.Key Facts
- Daraxonrasib targets mutated RAS proteins found in over 90% of pancreatic cancer cases.
- The drug was approved by the FDA faster than planned, reflecting its importance.
- Patients taking daraxonrasib lived a median of 13.2 months versus 6.7 months for those on chemotherapy.
- Side effects include skin rash, mouth sores, diarrhea, and digestive problems.
- Pancreatic cancer is very deadly and often diagnosed late when it has spread to other organs.
- About 67,000 new U.S. cases are expected this year with more than 52,000 deaths.
- Former Senator Ben Sasse, diagnosed with stage-four pancreatic cancer, reported significant benefit from the drug.
- The pill could lead to new treatments for other cancers with similar genetic mutations.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
